Clinical Trials

NSCLC

NCT05522660 2026-04-27

USZ-STRIKE

Phase 3 Recruiting

180 enrolled

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma

NCT02973789 2026-03-18

Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)

Phase 3 Completed

291 enrolled 22 charts

Carcinoma, Non-Small-Cell Lung

NCT03313804 2026-03-11

Priming Immunotherapy in Advanced Disease With Radiation

76 enrolled 9 charts

Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung

NCT07110103 2026-02-27

JACKPOT38

20 enrolled

SCLC

NCT06610734 2026-02-09

SKY

202 enrolled

Small Cell Lung Cancer Extensive Stage

NCT05348668 2026-01-07

Hybrid Dose-fraction Radiotherapy for Metastatic Non-small Cell Lung Cancer

78 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07171606 2025-12-18

A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer（NSCLC） Patients

240 enrolled

Phase 1/2 Active not recruiting

First-line Advanced NSCLC Patients

NCT05013450 2025-12-17

Dupilumab_Metastatic NSCLC

33 enrolled

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07271602 2025-12-09

A Phase 2 Randomized, Controlled Trial of QL1706 Plus Chemotherapy and Quad Shot for Driver Gene-negative Advanced Non-small Cell Lung Cancer.

104 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05440916 2025-12-02

PRIMM

50 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung

NCT06052852 2025-11-17

Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies

Phase 1 Terminated

17 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Melanoma, Ovarian Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT05846646 2025-10-20

Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC

Phase 2 Terminated

6 enrolled 7 charts

GenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell

NCT04681131 2025-09-25

CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC

85 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT05509699 2025-08-29

Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer

21 enrolled

Small Cell Lung Carcinoma

NCT06896422 2025-08-07

Randomized Trial of Glutathione With Anti-PD-1 and Chemotherapy in Advanced NSCLC

Phase 1 Recruiting

80 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06947694 2025-07-22

A Study on Exploring the Abscopal Effect Induced by Different Radioimmunotherapy Combination Patterns in the Treatment of Non-Small Cell Lung Cancer With Multiple Metastases

427 enrolled

NSCLC Stage IV Without EGFR/ALK Mutation

NCT05754203 2025-07-14

Efficacy and Safety of Super-hyperfractionation Pulse Radiotherapy Combined With ICIs for Advanced NSCLC

Phase NA Recruiting

40 enrolled

Phase 1 Active not recruiting

Lung Neoplasms

NCT05704985 2025-05-29

Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors

39 enrolled

DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Kidney Neoplasms, Neoplasms, Pancreatic Neoplasms, Skin Neoplasms, Colorectal Neoplasms

NCT06977074 2025-05-23

PROPHET

83 enrolled

Phase 1 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06966583 2025-05-12

NMN

20 enrolled

Phase 4 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06951841 2025-04-30

Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction

31 enrolled

Phase 2 Active not recruiting

Small Cell Lung Carcinoma

NCT04836728 2025-03-13

CCICC-002b

156 enrolled

Non-small Cell Lung Cancer Metastatic

NCT04997382 2025-02-25

CLASSIC5

112 enrolled

BreastDermatologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung

NCT03504488 2025-01-15

CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)

Phase 1/2 Completed

132 enrolled

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Melanoma, Triple Negative Breast Neoplasms

NCT06751849 2024-12-30

Neoantigen-loaded DC Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After Second-line Treatment

Advanced NSCLC

NCT06751901 2024-12-30

Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After Second-line Treatment

Advanced NSCLC

NCT06752044 2024-12-30

Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment

Phase NA Recruiting

Advanced NSCLC

NCT06752057 2024-12-30

Neoantigen-loaded DC Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment

Phase NA Recruiting

Advanced NSCLC

NCT06388031 2024-11-07

ICI Rechallenge for Advanced NSCLC With Long-Term Response to First-Line ICI

27 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05014464 2024-09-20

ATPase

90 enrolled

GastrointestinalHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung

NCT04721223 2024-09-19

JAB-3068 Activity in Adult Patients With Advanced Solid Tumors

Phase 1/2 Completed

12 enrolled

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT04322578 2024-06-04

CONFIRM

120 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05735028 2024-04-17

The Efficacy and Safety of PD-1/PD-L1 Inhibitors Combined With Centipeda Minima (CM) in Lung Cancer

Phase 1 Unknown

8 enrolled

Lung Neoplasms

NCT03511391 2024-01-23

CHEERS

DermatologicGenitourinaryHead & NeckThoracic

99 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Melanoma

NCT05248022 2024-01-09

Efficacy and Safety of DEB-BACE Combined With PD-1 Inhibitors in Stage II/III NSCLC With Standard Treatment Failure

Phase NA Unknown

98 enrolled